{
    "brief_title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies",
    "phase": "Phase 1",
    "drugs": "['GS-9716', 'Docetaxel', 'Sacituzumab Govitecan-hziy', 'Gemcitabine']",
    "drugs_list": [
        "GS-9716",
        "Docetaxel",
        "Sacituzumab Govitecan-hziy",
        "Gemcitabine"
    ],
    "diseases": "['Solid Malignancies']",
    "diseases_list": [
        "Solid Malignancies"
    ],
    "enrollment": "205.0",
    "inclusion_criteria": "Key inclusion criteria: \n\n Part A: GS-9716 Monotherapy \n\n Histologically or cytologically confirmed epithelial cancer, stage IV (metastatic) disease or locally advanced and unresectable (mixed histologies not permitted): \n\n Breast cancer \n\n Castrate-resistant prostate cancer not on hormonal androgen deprivation therapy \n\n Cervical cancer \n\n Colorectal cancer \n\n Endometrial cancer \n\n Epithelial ovarian cancer \n\n Esophageal cancer \n\n Follicular thyroid cancer \n\n Gastric or gastroesophageal junction adenocarcinoma \n\n Head and neck cancers- squamous cell carcinoma \n\n Hepatocellular carcinoma \n\n NSCLC \n\n Renal cell cancer (clear cell) \n\n Small-cell lung cancer \n\n Urothelial cancer \n\n Progressed after at least 1 prior standard therapeutic regimen, or for whom no standard therapy is available, standard therapy has failed, or for whom standard of care therapy is contraindicated \n\n Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 \n\n Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as described in protocol \n\n Adequate hematology, renal and hepatic function as described in the protocol \n\n All toxicity at screening \u2264 Grade 1, including peripheral neuropathy and excluding alopecia of any grade, well-controlled endocrine toxicities from prior immune checkpoint inhibitor therapy \u2264 Grade 2, and chronic electrolyte abnormalities requiring supplementation \u2264 Grade 2 \n\n Left ventricular ejection fraction (LVEF) \u2265 50% acquisition scan (MUGA) may be acceptable per discussion with the medical monitor \n\n Tissue criteria: Individuals must have available, sufficient, and adequate formalin-fixed tumor tissue sample or must agree to have a biopsy taken prior to entering the study to provide adequate tissue. Core needle or excisional biopsy or resected tissue is required. \n\n Part B and Part C: GS-9716 in Combination with Anticancer Therapies (All Cohorts) \n\n ECOG performance status of 0 or 1 \n\n Adequate hematology, renal and hepatic function as described in the protocol \n\n Otherwise, all toxicity at screening entry \u2264 Grade 1, including peripheral neuropathy and excluding alopecia of any grade, well-controlled endocrine toxicities from prior immune checkpoint inhibitor therapy \u2264 Grade 2, and chronic electrolyte abnormalities requiring supplementation \u2264 Grade 2 \n\n LVEF \u2265 50%, as well as no clinically significant pericardial effusion \n\n Tissue criteria: \n\n TNBC cohorts B3, C3, B4, C4: Individuals must have a tumor lesion that a mandatory pretreatment biopsy can be obtained from. Core needle, or excisional biopsy, or resected tissue is required. Fine needle aspirates and bone biopsies are not acceptable \n\n Cohorts B1, C1, B2, C2, B5, C5: Individuals must have available, sufficient, and adequate formalin-fixed tumor tissue sample or must agree to have a biopsy taken prior to entering the study to provide adequate tissue. Core needle or excisional biopsy or resected tissue is required. \n\n Cohorts B1, B2, C1, and C2: \n\n Histologically or cytologically confirmed unresectable metastatic or locally advanced, non-squamous NSCLC following treatment for metastatic disease including an immune checkpoint inhibitor and a single line of platinum-containing chemotherapy \n\n Individuals with bone metastases currently receiving bisphosphonates for palliation will be eligible providing informed consent can be given and that other qualifying sites of measurable disease are present. \n\n Cohorts B3, B4, C3, and C4: \n\n Histologically or cytologically confirmed TNBC based on the most recent analyzed biopsy or other pathology specimen. Triple-negative status for TNBC will be defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (US sites) or their equivalent (ex-US sites) \n\n Unresectable locally advanced or metastatic disease following only 1 prior standard therapeutic regimen for TNBC. Individuals who have received 2 or more prior systemic therapies are not eligible \n\n Individuals with bone metastases currently receiving bisphosphonates for palliation \n\n Individuals with stable, treated brain metastases will be eligible. \n\n Cohorts B5 and C5: \n\n Histologically proven soft tissue sarcoma (except the following histologies: gastrointestinal stromal tumors (GIST), Kaposi's sarcoma, mesotheliomas) which has been previously untreated for metastatic disease. \n\n Key ",
    "exclusion_criteria": ": \n\n Prior treatment with any myeloid cell leukemia 1 (MCL1) inhibitor \n\n Treatment with any high dose systemic corticosteroids within 2 weeks of the first dose of GS-9716. However, low dose corticosteroids \u2264 10 mg prednisone or equivalent daily is permitted \n\n Prior radiotherapy (or other nonsystemic therapy) within 2 weeks prior to dosing with GS-9716 \n\n Women who are pregnant or lactating \n\n Individuals with brain metastases may be enrolled only if treated, nonprogressive, and asymptomatic as well as off high dose steroids (> 10 mg prednisone or equivalent) for at least 4 weeks prior to dosing with GS-9716 \n\n History of leptomeningeal disease \n\n Individuals with active \u2265 Grade 2 nausea or vomiting, and/or signs of intestinal obstruction \n\n Known active or chronic hepatitis B or C infection or HIV infection or HIV positive \n\n Known history of unstable angina, myocardial infarction (MI), cardiac angioplasty or stenting, or clinically significant cardiac disease would include QT interval corrected for heart rate (QTc) interval > 450 ms for males and > 470 ms for females \n\n Known history of clinically significant active chronic obstructive pulmonary disease (COPD), or other moderate to severe chronic respiratory illness present within 6 months prior to dosing with GS-9716 \n\n Known history of clinically significant pulmonary interstitial lung disease, active interstitial lung disease, idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan \n\n Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (more frequently than once monthly) \n\n Prior history of clinically significant bleeding, intestinal obstruction, or gastrointestinal (GI) perforation within 6 months of initiation of study treatment \n\n Infection requiring intravenous anti-infective use within 2 weeks prior to dosing with GS-9716 \n\n Active or history of autoimmune disease or immune deficiency \n\n History of uncured coexisting cancer, not including uncured basal cell carcinoma, cervical cancer in situ, or superficial bladder cancer. \n\n Cohorts B1, B3, B5, C1, C3, and C5: \n\n Bilirubin > upper limit of normal (ULN). \n\n Cohorts B1, B2, C1, and C2: \n\n More than 1 prior chemotherapy regimen for metastatic non-squamous NSCLC; however, this would not exclude those who received frontline immune checkpoint inhibitor as monotherapy followed by a platinum-containing chemotherapeutic regimen in the second line \n\n Non-squamous NSCLC with targetable mutations (e.g., anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein kinase ROS (ROS1), v-RAF murine sarcoma viral oncogene homolog B (BRAF) for which approved therapies are available \n\n Cohorts B2 and C2 only: Prior therapy with sacituzumab govitecan-hziy or a topoisomerase 1 inhibitor or agents targeting Trop-2. \n\n Cohorts B3, B4, C3, and C4: \n\n More than 1 prior chemotherapy regimen for metastatic TNBC \n\n Cohorts B4 and C4 only: Prior treatment with sacituzumab govitecan-hziy or a topoisomerase 1 inhibitor or agents targeting Trop-2. \n\n Cohorts B5 and C5: \n\n Any previous treatment for metastatic disease \n\n Soft tissue sarcomas with the following histologies: GIST, Kaposi's sarcoma, or mesotheliomas. \n\n Note: Other protocol defined Inclusion/",
    "brief_summary": "The primary objective of Part A of this study is to define the maximum tolerated dose (MTD) or maximum administered dose of GS-9716 as monotherapy in advanced solid malignancies and to characterize the safety, and tolerability of GS-9716 monotherapy.~The primary objectives of Parts B and C of this study are: To characterize the safety, tolerability, and to define MTD and/or recommended Phase 2 dose (RP2D) of GS-9716 in combination with either docetaxel or sacituzumab govitecan-hziy in adults with metastatic non-squamous non-small cell lung cancer (NSCLC) following treatment for metastatic disease, including an immune checkpoint inhibitor and a single line of platinum containing chemotherapy (for Cohorts B1, B2, C1, and C2) and in adults with metastatic triple-negative breast cancer (TNBC) following a single line of therapy for metastatic disease (for Cohorts B3, B4, C3, and C4); To characterize the safety, tolerability, and to define MTD and/or the RP2D of GS-9716 in combination with gemcitabine and docetaxel in metastatic soft tissue sarcomas (mSTS) with nonspecific histologies previously untreated for metastatic disease (for Cohorts B5 and C5).",
    "NCT_ID": "NCT05006794"
}